Xenetic Biosciences (XBIO) Other Non-Current Liabilities (2014 - 2021)
Xenetic Biosciences' (XBIO) quarterly Other Non-Current Liabilities came in at $7957.0 in Q2 2021, down 54.71% on a QoQ basis from $17568.0 in Q1 2021.
Xenetic Biosciences (XBIO) Other Non-Current Liabilities (2014 - 2021) Analysis & Trends
Xenetic Biosciences (XBIO) has 7 years of Other Non-Current Liabilities data on file, last reported at $7957.0 in Q2 2021.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $7957.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $7957.0 (changed N/A YoY) and the FY2020 annual result came in at $27043.0, changed N/A from the prior year.
- Other Non-Current Liabilities eased to $7957.0 in Q2 2021, from $17568.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $27043.0 in Q4 2020 to a low of $4980.0 in Q3 2017.
- A 4-year average of $12735.1 and a median of $11567.5 in 2017 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 55.99% in 2017, down 79.86% in 2017.
- Tracing XBIO's Other Non-Current Liabilities over 4 years: stood at $4980.0 in 2017, then advanced by 24.06% to $6178.0 in 2019, then soared by 337.73% to $27043.0 in 2020, then slumped by 70.58% to $7957.0 in 2021.
- The last three Other Non-Current Liabilities figures came in at $7957.0 (Q2 2021), $17568.0 (Q1 2021), and $27043.0 (Q4 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 7,957.00 |
| Mar 31, 2021 | 17,568.00 |
| Dec 31, 2020 | 27,043.00 |
| Jun 30, 2019 | 6,178.00 |
| Mar 31, 2019 | 13,119.00 |
| Sep 30, 2017 | 4,980.00 |
| Jun 30, 2017 | 10,016.00 |
| Mar 31, 2017 | 15,020.00 |
| Dec 31, 2016 | 19,876.00 |
| Sep 30, 2016 | 24,733.00 |
| Jun 30, 2016 | 29,446.00 |
| Mar 31, 2016 | 34,127.00 |
| Dec 31, 2015 | 38,791.00 |
| Sep 30, 2015 | 43,270.00 |
| Jun 30, 2015 | 47,647.00 |
| Mar 31, 2015 | 52,153.00 |
| Dec 31, 2014 | 56,383.00 |
| Sep 30, 2014 | 60,729.00 |
| Jun 30, 2014 | 64,879.00 |
| Mar 31, 2014 | 70,611.00 |